Özdemir, N. Y. Et Al. 2010. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Medical Oncology , vol.27, no.3 , 680-684.

Özdemir, N. Y., AbalI, H., Öksüzoǧlu, B., Budakoglu, B., Uncu, D., Güler, T., ... OdabaşI, H.(2010). The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Medical Oncology , vol.27, no.3, 680-684.

Özdemir, Nuriye Et Al. "The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma," Medical Oncology , vol.27, no.3, 680-684, 2010

Özdemir, Nuriye Y. Et Al. "The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma." Medical Oncology , vol.27, no.3, pp.680-684, 2010

Özdemir, N. Y. Et Al. (2010) . "The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma." Medical Oncology , vol.27, no.3, pp.680-684.

@article{article, author={Nuriye Yildirim Özdemir Et Al. }, title={The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma}, journal={Medical Oncology}, year=2010, pages={680-684} }